Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation.
The post Novo Nordisk says experimental drug amycretin show 13% weight loss in trial appeared first on Reuters News Agency.